265 related articles for article (PubMed ID: 9596315)
1. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
O'Donnell AE; Barker AF; Ilowite JS; Fick RB
Chest; 1998 May; 113(5):1329-34. PubMed ID: 9596315
[TBL] [Abstract][Full Text] [Related]
2. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
3. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
[TBL] [Abstract][Full Text] [Related]
4. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
5. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
8. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
9. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
10. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
11. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
12. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.
Nasr SZ; Kuhns LR; Brown RW; Hurwitz ME; Sanders GM; Strouse PJ
Pediatr Pulmonol; 2001 May; 31(5):377-82. PubMed ID: 11340684
[TBL] [Abstract][Full Text] [Related]
13. Aerosolized deoxyribonuclease for cystic fibrosis.
Med Lett Drugs Ther; 1994 Apr; 36(920):34-5. PubMed ID: 8145672
[No Abstract] [Full Text] [Related]
14. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
17. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
18. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
